Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Rhea-AI Summary
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancer treatments, has scheduled its Q1 2025 financial results and business updates for Tuesday, May 13, 2025. The announcement will be made before US markets open, followed by a live webcast at 8:00 a.m. EDT.
Investors can access the press release through Adaptimmune's corporate website's investor section and join the webcast at https://www.gowebcasting.com/14032. For those preferring to dial in, the numbers are 1-833-821-0158 (US/Canada) or 1-647-846-2266 (International), with participants advised to connect 5-10 minutes before the start time.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ADAP declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.
The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-846-2266 (International). Callers should dial in 5-10 minutes prior to the scheduled start time and simply ask to join the Adaptimmune call.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on designing, developing, and delivering cell therapies to transform the lives of people with cancer. The Company's unique engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
###
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251137
FAQ
When will Adaptimmune (ADAP) release its Q1 2025 earnings?
What time is Adaptimmune's Q1 2025 earnings call?
How can I access Adaptimmune's Q1 2025 earnings call?
What does Adaptimmune Therapeutics (ADAP) specialize in?
